| MARSHFIELD CLINIC Patent applications |
| Patent application number | Title | Published |
|---|
| 20110251195 | ADRB2 GENE POLYMORPHISM ASSOCIATED WITH INTRAOCULAR PRESSURE RESPONSE TO TOPICAL BETA-BLOCKERS - The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved method for genotype-based prescribing of beta-blockers in glaucoma management. | 10-13-2011 |
| 20110189675 | Method For Administering Anticoagulation Therapy - The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype. | 08-04-2011 |
| 20090176870 | TGF-BETA MODULATORS AND METHODS FOR USING THE SAME - The present invention provides a method of modulating TGF-β activity in a subject. Methods of the present invention comprise administering to the subject an effective amount of a compound of the formula: | 07-09-2009 |
| 20090087856 | METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY - The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype. | 04-02-2009 |
